Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Roty
- Development stage
- Unknown
- Lead developer
- Pin Siang Medical Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Roty is a pharmaceutical drug marketed as film-coated tablets, primarily indicated for the treatment of hypercholesterolemia. Its active ingredient, rosuvastatin, belongs to the statin class of medications. Rosuvastatin functions as a competitive inhibitor of HMG-CoA reductase, an enzyme critical for cholesterol biosynthesis in the liver. By blocking this enzyme, Roty reduces the liver's production of cholesterol and enhances the clearance of low-density lipoprotein (LDL) cholesterol from the bloodstream. It is administered orally.
- Brand names
- RotyRoty F.C. Tablets
- Other names
- 諾酯替膜衣錠
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on Roty.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roty.